What is the recommended treatment with Valtrex (valacyclovir) for a pregnant woman with a viral infection, considering her medical history and potential fetal risks?

Valacyclovir Treatment in Pregnant Women

Primary Recommendation for Herpes Simplex Virus (HSV) Infection

For pregnant women with acute first-episode genital herpes, treat with valacyclovir 1 g orally twice daily for 7-10 days, and for women with recurrent genital herpes, initiate suppressive therapy with valacyclovir 1000 mg orally twice daily starting at 36 weeks gestation and continuing until delivery. 1, 2

Treatment Algorithm for HSV in Pregnancy

First Episode Genital Herpes:

• Valacyclovir 1 g orally twice daily for 7-10 days is the preferred regimen 1
• Alternative: Acyclovir 400 mg orally three times daily for 7-10 days 1
• For life-threatening maternal HSV infection (disseminated infection, encephalitis, pneumonitis, hepatitis), use intravenous acyclovir 5 mg/kg every 8 hours 1, 3

Recurrent Genital Herpes - Suppressive Prophylaxis:

• Begin at 36 weeks gestation with valacyclovir 1000 mg orally twice daily OR acyclovir 400 mg orally three times daily 2
• Continue until delivery 2
• This applies to all women with documented genital herpes during the current pregnancy 2

Safety Profile in Pregnancy

Valacyclovir and acyclovir are safe throughout pregnancy with no increased risk of major birth defects. 4

• Clinical data over several decades show no drug-associated risk of major birth defects 4
• The Acyclovir Pregnancy Registry documented 3.2% major birth defects with first-trimester exposure (95% CI: 2.0-5.0%), which is within the general population baseline of 2-4% 4
• The Valacyclovir Pregnancy Registry showed 4.5% major birth defects with first-trimester exposure (95% CI: 0.24-24.9%), also within normal range 4
• No consistent pattern of abnormalities has emerged from registry data 1, 4

Critical Context: Neonatal Transmission Risk

The timing of maternal HSV acquisition dramatically affects neonatal risk:

• Primary HSV infection acquired near delivery (third trimester): 30-50% neonatal transmission risk 2, 4
• Recurrent HSV at term: ≤3% neonatal transmission risk 1, 2
• Most mothers of infants with neonatal herpes lack histories of clinically evident genital herpes 1

Management at Delivery

Cesarean delivery is mandatory if visible genital lesions or prodromal symptoms are present at labor onset, regardless of primary versus recurrent disease. 2

• Cesarean delivery reduces transmission risk by approximately 85% when lesions are present 2
• Women without symptoms or signs of genital herpes at labor onset may deliver vaginally 1
• Viral cultures during pregnancy do not predict shedding at delivery and are not routinely indicated 1

Efficacy of Suppressive Therapy

Valacyclovir suppression starting at 36 weeks significantly reduces clinical HSV recurrences before delivery:

• Clinical recurrences reduced from 27.3% to 10.5% (RR 0.4,95% CI 0.2-0.9, P=0.023) 5
• However, HSV shedding within 7 days of delivery was similar between valacyclovir and placebo groups (10.4% vs 12.0%) 5
• Clinical lesions at delivery occurred in 5.3% with valacyclovir versus 14.6% with placebo (not statistically significant) 5

Special Populations

HIV-infected pregnant women:

• Same safety profile for valacyclovir 1
• Some experts recommend prophylaxis for those with frequent, severe recurrences 1
• Higher doses may be beneficial: acyclovir 400 mg orally three to five times daily 1

Immunocompromised patients:

• May require higher doses of acyclovir (400 mg orally three to five times daily) 1
• If lesions persist during treatment, suspect acyclovir resistance 1

Common Pitfalls to Avoid

Do not delay suppressive prophylaxis beyond 36 weeks gestation - the evidence base specifically supports initiation at 36 weeks, not earlier or later 2

Do not use topical antivirals for suppression - systemic oral therapy is required 2

Do not routinely treat asymptomatic infants delivered through an infected birth canal with acyclovir - reserve treatment for symptomatic infants or those with positive cultures 1

Do not assume viral cultures during pregnancy predict shedding at delivery - they are not routinely indicated 1

Neonatal Monitoring

All infants exposed to HSV during birth require:

• Careful clinical follow-up 1
• Viral cultures of mucosal surfaces obtained 24-48 hours after birth 1, 2
• Treatment reserved only for infants who develop clinical disease or have positive postpartum cultures 1

---

Valacyclovir for Cytomegalovirus (CMV) Infection in Pregnancy

Valacyclovir is NOT FDA-approved for CMV infection in pregnancy and should only be considered as off-label therapy in highly selected cases with documented fetal infection and high viral loads, after thorough multidisciplinary discussion. 6, 7

Evidence for CMV Treatment

Potential benefit in reducing vertical transmission:

• Meta-analysis showed valacyclovir reduced congenital CMV infection risk (pooled OR 0.37,95% CI 0.21-0.64, P<0.001) 7
• Benefit primarily seen with first-trimester maternal infection (pooled OR 0.34,95% CI 0.15-0.74, P=0.001) 7
• No significant benefit for periconceptional or third-trimester infections 7

Important limitations:

• Quality of evidence is very low on GRADE assessment 7
• Valacyclovir may control CMV infection only while administered 6
• Late transmission after treatment discontinuation is a documented risk 6
• One case series showed 17% transmission at amniocentesis but 42% at birth, with two women experiencing viremia reactivation after valacyclovir discontinuation 6

Dosing for CMV (Off-Label)

High-dose valacyclovir 8 g/day (2 g every 6 hours) has been used in research settings for pregnant women with primary CMV infection and high-risk features 6, 8, 9

Safety Concerns Specific to High-Dose Valacyclovir

Adverse events occur in 3.17% (95% CI 1.24-5.93%) of pregnant women taking valacyclovir: 7

• Acute renal failure in 1.71% (95% CI 0.41-3.39%), which resolved after discontinuation 7
• High-dose therapy (8 g/day) may interfere with IgG avidity maturation by reducing viral load and antigen presentation 9

Clinical Considerations for CMV

The risk of neonatal CMV infection varies by timing:

• Third-trimester acquisition: 30-50% neonatal infection risk 4
• Early pregnancy acquisition: approximately 1% neonatal infection risk 4
• Primary herpes in first trimester associated with neonatal chorioretinitis, microcephaly, and skin lesions 4

Valacyclovir for CMV remains investigational and should not be used routinely outside of research protocols or highly selected cases with documented fetal infection and severe manifestations. 6, 7